Table 2.
Circulating Biomarkers Measured in the Plasma of IPF and Control Participants
| Protein | Control n = 85 |
IPF n = 95 |
p-value |
|---|---|---|---|
| Activin A | 355.3 ± 193.9 | 418.4 ± 183.9 | 0.009 |
| ADAMTS13 | 932465.0 ± 431528.9 | 796302.1 ± 368128.0 | 0.022 |
| Eotaxin | 1148.9 ± 469.5 | 1440.8 ± 667.9 | 0.002 |
| Fas | 8688.8 ± 6202.1 | 7706.4 ± 2753.8 | 0.389 |
| GDF15 | 1463.2 ± 1542.3 | 2050.8 ± 1343.6 | < 0.001 |
| GROα | 246.1 ± 311.3 | 198.0 ± 99.5 | 0.331 |
| ICAM1 | 238606.1 ± 183090.8 | 259886.9 ± 161879.8 | 0.007 |
| IL1α | 6.7 ± 6.7 | 9.5 ± 15.0 | 0.112 |
| IL6 | 10.3 ± 16.8 | 9.7 ± 7.7 | 0.219 |
| IL7 | 3.1 ± 1.9 | 3.7 ± 1.9 | 0.022 |
| IL8 | 6.8 ± 4.3 | 9.0 ± 14.8 | 0.134 |
| IL10 | 22.1 ± 20.6 | 35.0 ± 42.5 | 0.015 |
| IL15 | 1.5 ± 1.3 | 1.5 ± 1.2 | 0.616 |
| MCP1 | 279.6 ± 88.6 | 363.2 ± 123.8 | < 0.001 |
| MDC | 454.8 ± 149.7 | 611.8 ± 215.3 | < 0.001 |
| MIP1α | 17.0 ± 16.6 | 22.1 ± 37.8 | 0.345 |
| MIP1β | 370.0 ± 1724.5 | 162.4 ± 59.5 | 0.629 |
| MMP1 | 764.3 ± 813.7 | 772.9 ± 433.2 | 0.017 |
| MMP7 | 2875.3 ± 2516.3 | 3828.2 ± 1591.5 | < 0.001 |
| MMP9 | 54523.0 ± 70865.2 | 49,906 ± 56381.2 | 0.582 |
| MPO | 82905.8 ± 111974.0 | 95750.7 ± 86099.0 | 0.031 |
| OPN | 72451.1 ± 75720.1 | 52389.8 ± 55664.1 | 0.086 |
| PAI1 | 20178.6 ± 11816.0 | 22684.1 ± 13130.5 | 0.188 |
| PARC | 53061.1 ± 32883.8 | 72900.6 ± 41964.7 | < 0.001 |
| RAGE | 1732.7 ± 829.4 | 1153.8 ± 554.2 | < 0.001 |
| RANTES | 23107.9 ± 15665.1 | 32923.4 ± 30574.4 | 0.004 |
| SOST | 442.8 ± 223.6 | 402.9 ± 207.6 | 0.183 |
| TARC | 433.1 ± 126.7 | 726.8 ± 720.0 | < 0.001 |
| TNFα | 9.2 ± 7.2 | 8.3 ± 5.3 | 0.466 |
| TNFR1 | 1518.2 ± 658.4 | 1370.0 ± 515.7 | 0.232 |
| TNFR2 | 3608.3 ± 1910.0 | 3312.8 ± 1670.1 | 0.275 |
| VEGFA | 42.3 ± 18.8 | 39.1 ± 16.2 | 0.380 |
Data expressed as mean ± SD.
p-value represents the comparison between IPF and control participants using the Kruskal-Wallis rank sum test.